Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 11/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 10/20 | 0.40 |
| ▸ | ATP4A | P20648 | 2/20 | 0.38 |
| ▸ | ATP4B | P51164 | 2/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7025445 | 1.00 | PPARG (0.45) | PPARGFFAR1PPARDPPARAATP4A | |
| SCHEMBL7028371 | 1.00 | PPARG (0.45) | PPARGFFAR1PPARDPPARAATP4A | |
| SCHEMBL6584128 | 0.86 | PPARG (0.62) | PPARGPPARAF2RL3 | |
| SCHEMBL8794428 | 0.85 | PPARG (0.41) | PPARGFFAR1PPARDPPARAATP4A | |
| SCHEMBL8794339 | 0.84 | FFAR1 (0.60) | PPARGFFAR1PPARDPPARA | |
| SCHEMBL7024314 | 0.82 | FFAR1 (0.41) | PPARGFFAR1PPARDPPARAATP4A | |
| SCHEMBL7162936 | 0.81 | FFAR1 (0.59) | PPARGFFAR1PPARDPPARA | |
| SCHEMBL7164834 | 0.80 | FFAR1 (0.58) | PPARGFFAR1PPARDPPARA | |
| SCHEMBL7025967 | 0.79 | FFAR1 (0.45) | PPARGFFAR1PPARDPPARAATP4A | |
| SCHEMBL8795234 | 0.78 | FFAR1 (0.62) | PPARGFFAR1PPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6147099-A | USEFUL AS ANTI-DIABETICS OR HYPOLIPIDEMIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, INC. (JP) | 2000-11-14 | — | — | US | claimed |
| US-7595333-B2 | Agent for improving acidosis | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-29 | — | — | US | disclosed |
| EP-1093370-B1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES | TAKEDA PHARMACEUTICAL (JP) | 2006-02-22 | — | — | EP | disclosed |
| US-20050239854-A1 | Body weight gain inhibitors | SUGIYAMA YASUO | 2005-10-27 | — | — | US | disclosed |
| US-20040106649-A1 | Agent for improving acidosis | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-06-03 | — | — | US | disclosed |
| US-20030134884-A1 | Neovascularization inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-07-17 | — | — | US | disclosed |
| EP-1304121-A1 | BODY WEIGHT GAIN INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-04-23 | — | — | EP | disclosed |
| US-20030060488-A1 | Drug comprising combination | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-03-27 | — | — | US | disclosed |
| EP-1277730-A1 | NEOVASCULARIZATION INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-01-22 | — | — | EP | disclosed |
| EP-1254667-A1 | DRUG COMPRISING COMBINATION | Takeda Chemical Industries, Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
| US-20020086885-A1 | Pharmaceutical composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2002-07-04 | — | — | US | disclosed |
| JP-2000212174-A | 2,4-OXAZOLIDINEDIONE DERIVATIVE, ITS PRODUCTION AND MEDICINAL COMPOSITION INCLUDING THE DERIVATIVE | TAKEDA CHEM IND LTD | 2000-08-02 | — | — | JP | disclosed |
| JP-2000191651-A | 2,4-OXAZOLIDINEDIONE DERIVATIVE, ITS PRODUCTION AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TAKEDA CHEM IND LTD | 2000-07-11 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086885-A1 | Pharmaceutical composition | GPR119, IAPP, PNLIP | PPARG 86/4885FFAR1 96/4885PPARD 276/4885 |
| US-20030060488-A1 | Drug comprising combination | TNF, HMGCR, TRAF6 | PPARG 443/4885FFAR1 298/4885PPARD 540/4885 |
| US-20050239854-A1 | Body weight gain inhibitors | PPARG, GPR119, PPARA | PPARG 1/4885FFAR1 43/4885PPARD 5/4885 |
| US-20040106649-A1 | Agent for improving acidosis | GPR119, SLC2A8, SLC2A1 | PPARG 422/4885FFAR1 77/4885PPARD 872/4885 |
| US-20030134884-A1 | Neovascularization inhibitors | VEGFA, FLT1, FLT4 | PPARG 1641/4885FFAR1 3421/4885PPARD 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.